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Abstract 
Aging is accompanied by the development of low grade systemic inflammation, termed 
‘inflammaging’, characterised by raised serum C-reactive protein (CRP) and pro-
inflammatory cytokines. Importantly, inflammaging is implicated in the pathogenesis of 
several of the major age-related diseases including cardiovascular disease, type 2 diabetes 
and dementia and is associated with increased mortality. The incidence of infection with the 
persistent herpes virus cytomegalovirus (CMV) also increases with age. Cross-sectional 
studies have proposed CMV infection as a significant driver of inflammaging, but a definitive 
case for CMV as a causative agent in inflammaging has not yet been made. We studied 
longitudinally 249 subjects (153 men, 96 women) who participated in the Hertfordshire 
Ageing Study at baseline (1993/5, mean age 67·5 years) and at 10 year follow up. At both 
times anthropometric measurements were made and subjects provided blood samples for 
analysis of inflammatory status and CMV seropositivity. In the cohort as a whole, serum CRP 
(p<0·02) and pro-inflammatory cytokines TNFα (p<0·001) and IL-6 (p<0·001) were 
increased between baseline and follow up sampling whereas levels of the anti-inflammatory 
cytokine IL-10 were decreased (p<0·001). These changes to cytokine status over time 
occurred equally in the 60% of subjects who were seropositive for CMV at baseline and 
follow up, the 8% who were CMV negative at baseline but who became CMV positive by the 
10 year follow up, and also in the 32% who were CMV seronegative throughout. We 
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Physiological aging is associated with a chronic sub-clinical systemic inflammatory state,  
termed inflammaging1, characterised by elevated levels of serum pro-inflammatory  
cytokines such as interleukin 6 (IL-6) and TNFα and acute phase proteins such as C-reactive 
protein (CRP)1.  Further, the levels of cytokines which counteract the inflammatory state, 
such as IL-10, are reduced with age2 compounding the inability to maintain immune 
homeostasis. Importantly, inflammaging is a predictor of frailty3 and chronic low grade 
inflammation is now accepted as a key pathogenic factor in the development of several age-
related pathologies including cardiovascular disease4 and type 2 diabetes5. Further, studies in 
centenarians6 show that these extremely long lived individuals maintain the cytokine profile 
of younger adults and do not develop inflammaging. Understanding the causes of 
inflammaging is therefore important for developing interventions to prevent its occurrence 
and extend the healthy lifespan of our aging population. 
Various factors have been proposed to drive inflammaging including increased adiposity with 
age7, and decreased production of sex steroids8, but one of the dominant theories is that 
inflammaging is driven in large part by the sustained efforts of the immune system to control 
infections with persistent herpes viruses, most notably cytomegalovirus9. Cytomegalovirus 
(CMV) is a prevalent β-herpes virus infecting 60-85% of the Western population and 
approximately 80-90% of those over 65 years10.  CMV infection has been shown to induce 
IL-6 and TNFα production by leukocytes11 and CMV seropositivity is in turn associated with 
increased all-cause mortality10,12. These observations have led to the suggestion that CMV 
infection is a major driver of inflammaging and that this effect contributes to the increased 
morbidity and mortality associated with infection.  Moreover, if correct, this would suggest 
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improve health in old age. To date no longitudinal studies have been reported to confirm a 
link between CMV infection and inflammaging.  
The aim of this study was to determine the impact of CMV infection on serum pro- and anti-
inflammatory cytokine levels in a 10 year longitudinal study of older adults, comparing 
individuals who were CMV seronegative throughout, those who acquired CMV during the 10 
year period, and those who were CMV seropositive at baseline and follow up. Sera were 
available from 249 subjects at both baseline and 10 year follow up and the mean age at study 
entry was 67·5 ± 2·4 years. CMV antibody status was determined on serum at both time 
points and revealed that 149 (60%) of donors were CMV seropositive at entry and follow up 
(CMV+/+), 80 (32%) remained CMV seronegative throughout the study (CMV-/-) and 20 
subjects (8%) converted from being CMV negative to CMV positive (CMV-/+) during the 10 
year study period.  
Analysis of serum CRP and pro- and anti-inflammatory cytokines revealed a profile of 
increased systemic inflammation during aging in line with previous observations1 (Figure 1).  
IL-6 (Figure 1A) concentrations increased 2.3 fold over time (F(1,154) = 117·3, p < 0·001; η2 
= 0·432) whilst TNFα (Figure 1B) showed a dramatic 4.3 fold increase over the 10 year 
period  (F(1,104) = 126·5, p < 0·001; η2 = 0·549). CRP (Figure 1C) levels were 1.2 fold 
higher between follow up and baseline (F(1,240) = 5·0, p = 0·026; η2 = 0·021). In addition, 
levels of the anti-inflammatory cytokine IL-10 (Figure 1E) decreased by 65 % between the 
baseline and follow up samplings (F(1,53) = 42·8, p < 0·001; η2 = 0·447). However we saw 
no change in IFNγ (F(1,199) = 1·7, p = 0·188; η2 = 0·009) (Figure 1D).  
When the analysis was repeated for the three different CMV groupings we found that similar 
increases in both IL-6 and TNFα occurred between baseline and follow up in all three groups 
(Figure 2A and 2B). IL-6 showed a 2.4, 2.2 and 2.4 fold increase in the CMV-/+ (p = 0·03), 
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and 4.1 fold increase in TNFα was seen in each of these subsets over time (all p < 0·001). 
Interestingly, the CRP level did not change over time in the CMV-/- group (p = 0·736) or the 
CMV -/+ group (p = 0.541) but did show a significant increase in the CMV+/+ (p = 0·004) 
group (Figure 2C). As CRP production has a well-defined relationship with IL-6; we assessed 
the association of IL-6 and CRP to investigate further CRP increases observed in the 
CMV+/+ group. To determine the relationship of IL-6 with CRP in each group we ran a 
linear regression analysis with baseline and follow-up IL-6 entered as predictors of follow-up 
CRP. Follow-up CRP was positively associated with IL-6 in the cohort as a whole (β = .194, 
p = .023, ΔR2 = .032) highlighting the physiological relationship between IL-6 and CRP 
production. Following this we analysed the contribution from each CMV serostatus group. 
There was no association with IL-6 and CRP in either the CMV-/- (β = .240, p = .125, ΔR2 = 
.046) or the CMV-/+ (β = .266, p = .443, ΔR2 = .050) groups whilst in the CMV+/+ group 
CRP was positively associated with IL-6 (β = .212, p = .049, ΔR2 = .041). These data suggest 
that elevated CRP levels are in part driven by increased IL-6 concentrations if exposed to 
CMV but this appears to be related to length of CMV exposure.  Also as there was no change 
in the CRP levels for the donors that seroconverted for CMV infection during the study 
period, this suggests that factors other than CMV infection may also be influencing increases 
in CRP in the CMV+/+ group.  
In our cohort IL-10 showed a 0.8 fold and 0.5 fold reduction in the CMV-/- (p = 0·001) and 
CMV+/+ (p = 0·01) groups respectively and a trend towards a reduction in the CMV-/+ (p = 
0·07) group (Figure 2E). Interestingly, these changes were seen only in male subjects (data 
not shown). Gender differences for IL-10 production have been suggested previously and 
may reflect an increased incidence of autoimmunity in females2. The serum level of IFNγ did 
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seen in any of the three CMV groupings (Figure 2D), CMV-/+ (p = 0·928), CMV-/- (p = 
0·401) and CMV+/+ (p = 0·474).  
Taken together our data suggest that mechanisms other than the immune response to CMV 
infection are driving the increase in systemic inflammation that is observed with normal 
physiological aging. The longitudinal OCTO-Immune and NONA-Immune studies followed 
small cohorts of the very elderly (>85 years) for up to 6 years and correlated various immune 
markers with mortality. These studies were the first to define a set of parameters termed the 
“immune risk profile” which was associated with increased mortality during follow up. 
Interestingly, these included CMV seropositivity and a profile of raised pro-inflammatory 
markers12,13. However, these studies did not compare the inflammatory status of individuals 
who remained CMV-seronegative or who seroconverted in the 6 year study period. Similarly, 
Roberts et al14 conducted a prospective analysis of CMV titres and found that increased titre 
was associated with increased TNFα, IL-6 and raised mortality but did not consider 
longitudinal differences between CMV seronegative and seropositive individuals. Our study 
is thus the first to address the impact of CMV serostatus on the increase in inflammatory 
markers during aging using longitudinal data and reveals that chronic systemic inflammation 
occurs independently of CMV infection.  
Several genetic and environmental factors may contribute to inflammaging. IL-6 
polymorphisms (174G>C) are associated with elevated IL-6 levels and increase in prevalence 
in the over 65 year olds15, possibly reflecting an evolutionary benefit of a robust pro-
inflammatory response in early life which is not conducive to a healthy old age. Indeed raised 
inflammatory cytokines such as IL-6 are not seen in centenarians6 or members of families 
with extended longevity16, supporting the notion that an anti-inflammatory genotype is 
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inflammageing are the age-related increase in adiposity7, reduced physical activity17, the loss 
of sex hormones during menopause18 and andropause8 which are all known to increase 
systemic inflammation. 
Our study has some limitations. Firstly, we did not consider the impact of other latent viral 
infections such as Epstein Barr virus and Varicella Zoster Virus, which might possibly 
contribute to inflammation in the CMV negative grouping.  Secondly, due to the relatively 
small size of the cohort as a whole and the low seroconversion rate for CMV during the study 
period, the size of the CMV-/+ and CMV -/- groups are quite small and the impact of 
serostatus on serum markers should be addressed in a larger study. Finally, study participants 
were lost to follow-up between the 1993/5 baseline and 2003/5 follow-up clinics due to a 
variety of reasons (including 121 to mortality, loss to follow-up, refusal to participate) and we 
have previously shown that a healthy participant effect is, unsurprisingly, evident in HAS19. 
In the current study, the 153 men who went on to have CMV status classified at the 2003/5 
HAS follow-up were significantly (p<0·05) younger, less likely to be current smokers, were 
of higher social class, and had lower IL-6 and CRP levels at the baseline clinic than the 258 
men who only participated in the baseline study. Selection effects were less evident for 
women; the 101 women who were sampled at both time points were significantly (p<0·05) 
less likely to be current smokers than the 205 women who only participated in the baseline 
study, but were otherwise similar. These selection effects have the potential to bias our 
results. However, our analyses were internal to the HAS sample; bias would only be 
introduced if the associations between CMV status and inflammaging were systematically 
different among those who participated in our study, and those who did not; this seems 
unlikely.  
In conclusion, CMV infection does not appear to determine the age-related increase in serum 
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in the population would have little or no impact on the inflammatory profile of aging 
individuals. However, it is well established that the cellular immune response against CMV is 
extremely immunodominant and increases further in older adults20, occupying valuable 
“immune space” and potentially impairing the response to other pathogens and to vaccination 
in old age. Further epidemiological analyses of the impact of CMV infection on health status 
in the elderly thus remain warranted. 
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Legends to Figures  
Figure 1. Cytokine and CRP concentrations at baseline and 10 year follow up in subjects in 
the Hertfordshire Ageing Study. Significant increases over time were observed for serum 
concentrations of  IL-6 (A), TNFα (B) and CRP (C) whilst a decrease was observed for IL-10 
(E). No differences over time were observed for IFNγ (D). Results are mean ± SEM analysed 
by mixed model repeated measures ANOVA. *p<0·03, **p<0·001 for baseline compared 
with 10 year follow up. 
Figure 2. Impact of CMV serostatus and aging on serum cytokine and CRP concentrations. 
Subjects were grouped by CMV serostatus as either negative at baseline and positive at 10-
year follow-up (CMV-/+), negative at both time points (CMV-/-), or positive at both time 
points (CMV+/+). Serum IL-6 (A) and TNFα (B) concentrations increased in all 3 CMV 
groups. CRP (C) was only increased in the CMV+/+ group, while the anti-inflammatory 
cytokine IL-10 (E) was decreased in the CMV-/- and CMV+/+ groups and a trend (p=.07) 
towards a reduction was observed in the CMV-/+. IFNγ (D) was unchanged for all groups. 
Results are mean ± SEM analysed by mixed model repeated measures ANOVA with 
Bonferroni corrected pair wise comparisons. * p<0·05, **p<0·01, ***p<0·001 for baseline 
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